BioVendor brings a unique diagnostic advantage with a fully automated CLIA panel combining functional markers C-peptide and Insulin with autoimmune markers GAD65 and IA-2, supporting faster and more accurate diabetes differentiation.
BioVendor is introducing a comprehensive diabetes panel that integrates both functional and autoimmune markers into a single, fully automated CLIA workflow. This solution provides a unique market advantage by offering GAD65 and IA-2 markers in a CLIA format, enabling more precise and earlier differentiation between Type 1, Type 2, and LADA diabetes. By replacing traditional ELISA and RIA methods, the platform significantly enhances laboratory efficiency and safety through faster processing, higher throughput, and the elimination of radioactive materials.
At BioVendor, we are committed to delivering innovative solutions that enhance diagnostic accuracy, streamline laboratory workflows, and support superior patient care. To this end, we are proud to introduce a comprehensive diabetes panel designed to offer a holistic view of pancreatic function and autoimmune etiology. While the importance of thorough diabetes diagnostics continues to grow, laboratories have frequently encountered limitations when attempting to integrate these essential markers into a single, unified workflow.
By consolidating functional markers—such as C-peptide and Insulin—with autoimmune markers like GAD65 and IA-2 within a single panel, laboratories can achieve more precise differentiation between Type 1 diabetes, LADA, and Type 2 diabetes. This integration also facilitates the early identification of autoimmune diabetes in patients exhibiting atypical disease progression or ambiguous clinical classifications.
Traditionally, functional and autoimmune diabetes markers have been assessed independently, often utilizing disparate methods or platforms. This fragmented approach can delay diagnosis and complicate clinical classification. Furthermore, markers such as GAD65 and IA-2 have primarily been accessible via ELISA or RIA methods, which demand significant manual handling and extended processing times. CLIA offers a faster, more standardized alternative, providing higher throughput without the need for radioactive materials.
A primary advantage of the BioVendor Group solution is the unique availability of GAD65 and IA-2 in a fully automated CLIA format—a capability that sets our platform apart from others in the market.
Learn more about CLIA-based diabetes differentiation
Beyond diabetes: Broader clinical value
The BioVendor Group CLIA solution offers benefits far beyond diabetes diagnostics alone. By integrating diabetes markers with infectious serology, autoimmunity testing, and additional clinical markers on a single platform, laboratories can broaden their diagnostic range while simplifying workflows, reducing operational complexity, and enhancing overall efficiency.
Why choose the BioVendor Group diabetes panel?
- Precision in diabetes classification: The combination of functional and autoimmune markers ensures a more reliable distinction between Type 1, LADA, and Type 2 diabetes.
- Unique CLIA availability for GAD65 and IA-2: Accessing GAD65 and IA-2 in a fully automated CLIA format provides a distinct diagnostic advantage not commonly found on other platforms.
- Enhanced laboratory efficiency: Full automation minimizes manual intervention, reducing hands-on time and driving higher productivity.
- Rapid, standardized testing: Compared to traditional ELISA, CLIA testing provides faster analysis, superior throughput, and more consistent results.
- A safer alternative to RIA: Unlike RIA methods, CLIA eliminates the need for radioactive materials, resulting in a safer and more manageable laboratory environment.